Medicenna Therapeutics Corp. announced a subscription agreement of a non-brokered private placement of 5,141,388 common shares at a price of CAD1.95 per share for a gross proceeds CAD 10,025,706.6 and 5,141,388 pre-funded warrants to purchase 5,141,388 common shares at a price of CAD1.94 per share for a gross proceeds CAD 9,974,292.72, bringing total proceeds to CAD 19,999,999.32 on April 26, 2024. The transaction includes participation from RA Capital Healthcare Fund, L.P. The Offering is expected to close on or about April 30, 2024 and is subject to the approval of the TSX.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.14 CAD | +12.63% | +14.44% | +409.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+409.52% | 121M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding